Access to medicines in the developing world

Our aim is to provide universal access to our medicines, particularly for low- and middle-income countries in the developing world. We rely on a number of company-wide policies, programs and innovative initiatives to guide our efforts.

Neglected tropical diseases (NTDs)
Commitment to patients
We work hard to develop treatments to address unmet medical needs and then work even harder to enhance access. We’ve developed specific policies to help guide our efforts for universal access to our medicines.
Access management
Here are specific programs and partnerships to help facilitate and manage access to our medicines.
Research and development
Our R&D efforts address important unmet medical needs across a number of disease and therapeutic areas.
Partnering with patients and physicians
Patient assistance and support programs take various forms in different countries around the world. See how we work locally to help patients get the medicines they need.
Clinical trials
We enable health care institutions in other countries to strengthen their own clinical trial capabilities.
Improving healthcare infrastructure and practices
By improving local health care infrastructure, we support an environment where patients can get the most innovative treatments.
Patents, licensing, and technology transfer
We are committed to ensuring that patents do not prevent access to therapy in resource-constrained countries.
Product quality and safety
We are committed to providing the highest quality products and ensuring product integrity throughout the product lifecycle.
Drug donations and philanthropic efforts
We support philanthropic efforts to promote health equity and improve the health outcomes of populations disproportionately affected by serious diseases and conditions.
HCV developing world strategy
We believe in a coalition approach to enable global access to HCV treatment in the developing world.